Search - tctmd.com

Displaying 41 - 60 of 62

Sort: Relevancy | Date

Presentation TCT 2013

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

Presenter: Clemens von Birgelen

October 31, 2013

News Conference News TCT 2013

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

October 31, 2013

News Industry News

Comparison of Two Third-Generation Drug-Eluting Stents Establishes Comparable Safety and Efficacy; Demonstrates Non-Inferiority of Newest Zotarolimus-Eluting Stent

October 31, 2013

Presentation TCT 2013

Insights from the TWENTE Series of Clinical Trials: Past, Present, and Future

Presenter: Clemens von Birgelen

October 28, 2013

News Daily News

TWENTE: Still Few Differences between ZES and EES at 2 Years

L.A. McKeown

May 03, 2013

News Daily News

TWENTE: Sigue habiendo Pequeñas Diferencias entre los SLZ y los SLE a los 2 Años

L.A. McKeown

May 03, 2013

Presentation TCT 2013

Clinical Outcome of Diabetic and Non-Diabetic Patients Treated With Second-Generation Zotarolimus-Eluting and Everolimus-Eluting DES

Presenter: Kenneth Tandjung, Hanim Sen, Mounir Basalus, K Gert van Houwelingen, Marije L?wik, Martin Stoel, Frits de Man, J. Hans Louwerenburg, Gerard Linssen, Mark Nienhuis, Rogier Nijhuis, Job van der Palen, Clemens von Birgelen

January 31, 2013

Presentation TCT 2012

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

Topic Essentials(5)

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

Preintervention IVUS: From Intermediate Lesion Assessment to High-Risk Plaques

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

VH-IVUS: Cath Lab Basics

Presenter: Clemens von Birgelen

October 24, 2012

Presentation TCT 2012

Using IVUS for Assessment and Treatment Guidance of PCI Complications

Presenter: Clemens von Birgelen

October 24, 2012

Presentation TCT 2012

TCT-47. Two-year Clinical Outcome of the TWENTE Trial, A Randomized Controlled Trial Comparing Second-generation Zotarolimus-eluting Resolute Stents vs. Everolimus-eluting...

Presenter: Clemens von Birgelen

October 23, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

L.A. McKeown

February 20, 2012

Presentation TCT 2012

Incidence of Periprocedural Myocardial Infarction Following Stent Implantation: Comparison Between First and Second Generation Drug-Eluting Stents

Presenter: Kenneth Tandjung, Mounir W. Basalus, Esther Muurman, Hans Louwerenburg, K. Gert van Houwelingen, Martin G. Stoel, Frits H. de Man, Hanneke Jansen, Jennifer Huisman, Gerard C. Linssen, Herman T. Droste, Mark B. Nienhuis, Clemens von Birgelen

January 03, 2012

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Industry News

Head-to-head comparison of two second generation drug-eluting coronary stents demonstrates non-inferiority

November 10, 2011

Partner Content

Ultrathin Orsiro DES: Novel technology, eye-catching cases and robust evidence

March 7, 2019

CME

Drug Eluting Stents: How Low Can Events Go? Integrating New Randomized Trial Data Into Clinical Practice

Video

» Interview

TCT 2018: Dr. C. Michael Gibson talks with Dr. Clemens von Birgelen about the BIONYX trial

September 22, 2018

Advertisement

DUTCH PEERS (TWENTE II): A Prospective, Randomized, "All-Comers" Trial of Third-Generation Zotarolimus-Eluting Stents vs. Everolimus-Eluting Coronary Stents

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

Comparison of Two Third-Generation Drug-Eluting Stents Establishes Comparable Safety and Efficacy; Demonstrates Non-Inferiority of Newest Zotarolimus-Eluting Stent

Insights from the TWENTE Series of Clinical Trials: Past, Present, and Future

TWENTE: Still Few Differences between ZES and EES at 2 Years

TWENTE: Sigue habiendo Pequeñas Diferencias entre los SLZ y los SLE a los 2 Años

Clinical Outcome of Diabetic and Non-Diabetic Patients Treated With Second-Generation Zotarolimus-Eluting and Everolimus-Eluting DES

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

Topic Essentials(5)

Preintervention IVUS: From Intermediate Lesion Assessment to High-Risk Plaques

VH-IVUS: Cath Lab Basics

Using IVUS for Assessment and Treatment Guidance of PCI Complications

TCT-47. Two-year Clinical Outcome of the TWENTE Trial, A Randomized Controlled Trial Comparing Second-generation Zotarolimus-eluting Resolute Stents vs. Everolimus-eluting...

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

Incidence of Periprocedural Myocardial Infarction Following Stent Implantation: Comparison Between First and Second Generation Drug-Eluting Stents

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

Head-to-head comparison of two second generation drug-eluting coronary stents demonstrates non-inferiority

Ultrathin Orsiro DES: Novel technology, eye-catching cases and robust evidence

Drug Eluting Stents: How Low Can Events Go? Integrating New Randomized Trial Data Into Clinical Practice

TCT 2018: Dr. C. Michael Gibson talks with Dr. Clemens von Birgelen about the BIONYX trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content